1. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. (5th April 2022) Authors: Mateos, M; Hari, P; Bahlis, N; Chari, A; van de Donk, NWCJ; Dholaria, B; Garfall, AL; Goldschmidt, H; Kortüm, KM; Krishnan, A; Martin, T; Morillo, D; Oriol, A; Reece, D; Rodriguez, C; Rodríguez-Otero, P; San-Miguel, JF; Usmani, SZ; Verona, R; Lin, SXW Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1. (5th April 2022) Authors: van de Donk, N. W. C. J; Minnema, M C; Berdeja, J G; Oriol, A; Krishnan, A; Rodríguez-Otero, P; Askari, E; Mateos, M; Costa, L. J; Verona, R; Ma, J; Girgis, S; Yang, S; Hilder, B. W; Russell, J; Goldberg, J. D; Chari, A Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗